NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Tschandl, Philipp ^a   Berghoff, Anna Sophie ^b   Preusser, Matthias ^b   Burgstaller Muehlbacher, Sebastian ^a   Pehamberger, Hubert ^a   Okamoto, Ichiro ^a   Kittler, Harald ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BRAF GENE; CANCER RISK; CELL CULTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MELANOCYTIC NEVUS; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE N RAS; PROTEIN EXPRESSION; SKIN CARCINOGENESIS;

DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; MUTATION RATE; NEVUS, PIGMENTED; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84879952154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069639     Document Type: Article

References (47)

1. Clark WH Jr., Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ, (1978) Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 114: 732-738. doi:10.1001/archderm.114.5.732. PubMed: 646394.
2. Clark WH Jr., Elder DE, Guerry Dt, Epstein MN, Greene MH, et al. (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15: 1147-1165. doi:10.1016/S0046-8177(84)80310-X. PubMed: 6500548.
3. Greene MH, Clark WH Jr., Tucker MA, Elder DE, Kraemer KH, et al. (1985) Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med 312: 91-97. doi:10.1056/NEJM198501103120205. PubMed: 3964923.
4. Hussein MR, (2005) Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol 58: 453-456. doi:10.1136/jcp.2004.019422. PubMed: 15858113.
5. Miller AJ, Mihm MC Jr., (2006) Melanoma. N Engl J Med 355: 51-65. doi:10.1056/NEJMra052166. PubMed: 16822996.
6. Uribe P, Wistuba II, Gonzalez S, (2009) Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathol 31: 354-363. doi:10.1097/DAD.0b013e318185d205. PubMed: 19461239.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. doi:10.1038/nature00766. PubMed: 12068308.
8. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147. doi:10.1056/NEJMoa050092. PubMed: 16291983.
9. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, et al. (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16: 267-273. doi:10.1097/01.cmr.0000222600.73179.f3. PubMed: 16845322.
10. Thomas NE, (2006) BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16: 97-103. doi:10.1097/01.cmr.0000215035.38436.87. PubMed: 16567964.
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819. doi:10.1056/NEJMoa1002011. PubMed: 20818844.
12. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703. doi:10.1056/NEJMoa1210093. PubMed: 23020132.
13. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365. doi:10.1016/S0140-6736(12)60868-X. PubMed: 22735384.
14. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ, (2001) Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 117: 1483-1489. doi:10.1046/j.0022-202x.2001.01601.x. PubMed: 11886512.
15. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J, (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res Off J Am Assoc Cancer Res 9: 6483-6488. PubMed: 14695152.
16. Dong J, Phelps RG, Qiao R, Yao S, Benard O, et al. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 3883-3885. PubMed: 12873977.
17. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA, (2009) Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 129: 1483-1488. doi:10.1038/jid.2008.374. PubMed: 19037234.
18. Rosso R, Romagosa Y, Kirsner RS, (2009) Progression of NRAS and BRAF mutations in cutaneous melanoma. J Invest Dermatol 129: 1318. doi:10.1038/jid.2009.107. PubMed: 19434085.
19. Wu J, Rosenbaum E, Begum S, Westra WH, (2007) Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 29: 534-537. doi:10.1097/DAD.0b013e3181584950. PubMed: 18032947.
20. Loewe R, Kittler H, Fischer G, Faé I, Wolff K, et al. (2004) BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 123: 733-736. doi:10.1111/j.0022-202X.2004.23402.x. PubMed: 15373778.
21. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20. PubMed: 12447372.
22. Uribe P, Wistuba II, González S, (2003) BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25: 365-370. doi:10.1097/00000372-200310000-00001. PubMed: 14501284.
23. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR, (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374. doi:10.1016/j.cell.2007.12.032. PubMed: 18267069.
24. Decarlo K, Yang S, Emley A, Wajapeyee N, Green M, et al. (2010) Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol 41: 886-894. doi:10.1016/j.humpath.2009.12.002. PubMed: 20233623.
25. Schrama D, Kneitz H, Willmes C, Adam C, Houben R, et al. (2010) Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma. J Invest Dermatol 130: 897-898. doi:10.1038/jid.2009.304. PubMed: 19829302.
26. Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, et al. (2010) IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell 141: 717-727. doi:10.1016/j.cell.2010.04.021. PubMed: 20478260.
27. Papp T, Schipper H, Kumar K, Schiffmann D, Zimmermann R, (2005) Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res 15: 401-407. doi:10.1097/00008390-200510000-00008. PubMed: 16179867.
28. Zalaudek I, Guelly C, Pellacani G, Hofmann-Wellenhof R, Trajanoski S, et al. (2011) The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J Invest Dermatol 131: 542-545. doi:10.1038/jid.2010.332. PubMed: 21068756.
29. Meyer LJ, Piepkorn M, Goldgar DE, Lewis CM, Cannon-Albright LA, et al. (1996) Interobserver concordance in discriminating clinical atypia of melanocytic nevi, and correlations with histologic atypia. J Am Acad Dermat 34: 618-625. doi:10.1016/S0190-9622(96)80061-2. PubMed: 8601651.
30. Pollock PM, Meltzer PS, (2002) A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2: 5-7. doi:10.1016/S1535-6108(02)00089-2. PubMed: 12150818.
31. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG, (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126: 154-160. doi:10.1038/sj.jid.5700026. PubMed: 16417231.
32. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H, (2003) Cutaneous melanomas associated with nevi. Arch Dermatol 139: 1620-1624; discussion 1624. doi:10.1001/archderm.139.12.1620. PubMed: 14676081.
33. Tsao H, Bevona C, Goggins W, Quinn T, (2003) The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 139: 282-288. doi:10.1001/archderm.139.3.282. PubMed: 12622618.
34. Rhodes AR, Mihm MC Jr., Weinstock MA, (1989) Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol Off J United States Canadian Academy Of Pathology, Inc 2: 306-319. PubMed: 2762287.
35. Clemente C, Cochran AJ, Elder DE, Levene A, MacKie RM, et al. (1991) Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol 22: 313-319. doi:10.1016/0046-8177(91)90078-4. PubMed: 1741810.
36. de Wit PE, van't Hof-Grootenboer B, Ruiter DJ, Bondi R, Bröcker EB, et al. (1993) Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 29A: 831-839. PubMed: 8484972.
37. Pozo L, Naase M, Cerio R, Blanes A, Diaz-Cano SJ, (2001) Critical analysis of histologic criteria for grading atypical (dysplastic) melanocytic nevi. Am J Clin Pathol 115: 194-204. doi:10.1309/KXJW-1UJE-BPG6-AXBV. PubMed: 11211607.
38. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, et al. (2012) Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLOS ONE 7: e29336. doi:10.1371/journal.pone.0029336. PubMed: 22235286.
39. Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, et al. (2013) Detection of BRAF p.V600E Mutations in Melanomas: Comparison of Four Methods Argues for Sequential Use of Immunohistochemistry and Pyrosequencing. J Mol Diagn JMD 15: 94-100. doi:10.1016/j.jmoldx.2012.09.001. PubMed: 23159108.
40. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, et al. (2013) Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. Am J Surg Pathol 37: 61-65. doi:10.1097/PAS.0b013e31826485c0. PubMed: 23026937.
41. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, et al. (2012) A landscape of driver mutations in melanoma. Cell 150: 251-263. doi:10.1016/j.cell.2012.06.024. PubMed: 22817889.
42. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, et al. (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36: 844-850. doi:10.1097/PAS.0b013e318246b527. PubMed: 22592144.
43. Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, et al. (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123: 223-233. doi:10.1007/s00401-011-0887-y. PubMed: 22012135.
44. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, et al. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294-303. doi:10.1016/j.ccr.2009.02.022. PubMed: 19345328.
45. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724. doi:10.1038/nature03890. PubMed: 16079850.
46. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O, (1989) Association of early malignant melanoma with nevocytic nevi. Cancer 63: 550-555. doi:10.1002/1097-0142(19890201)63:3. PubMed: 2643457.
47. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, et al. (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122: 11-19. doi:10.1007/s00401-011-0841-z. PubMed: 21638088.